StockData
Apimeds Pharmaceuticals US, Inc. logo

Apimeds Pharmaceuticals US, Inc. (APUS) stock

APUSNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 16, 2026Score 1/30
$1.89−0.06 (-3.08%)

Close on Nov 18, 2026Market cap $2.85MP/E –Yield –

Apimeds Pharmaceuticals US net income

Net income is the profit left for shareholders after every expense, interest and tax.

Apimeds Pharmaceuticals US's net income for the twelve months ending Sep 30, 2026 was -$22.74M. For fiscal 2025 it was -$6.00M.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$6.00M–
FY2024Dec 31, 2024-$1.39M–
FY2023Dec 31, 2023-$777.69K–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$33.65M–
Q2 FY2026Jun 30, 2026-$20.17M–
Q1 FY2026Mar 31, 2026-$35.06M–
Q4 FY2025Dec 31, 2025-$1.16M–
Q3 FY2025Sep 30, 2025-$1.78M–
Q2 FY2025Jun 30, 2025-$2.66M–
Q1 FY2025Mar 31, 2025-$402.40K–
Q4 FY2024Dec 31, 2024-$311.63K–
Q3 FY2024Sep 30, 2024-$332.52K–
Q2 FY2024Jun 30, 2024-$449.36K–
Q1 FY2024Mar 31, 2024-$296.47K–

More Apimeds Pharmaceuticals US figures

See a number that looks wrong?